Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Biotechnology

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Revenue projections:

Revenue projections for VRTX
Revenue projections for VRTX

Revenues for Vertex Pharmaceuticals Incorporated are forecasted to decline from last year's levels, prompting caution among investors. When revenues fall, it can have a significant negative impact on the company's bottom line, reducing profitability and making the stock less attractive to risk-averse investors.

Financial Ratios:

currentRatio 2.901000
forwardPE 19.515295
debtToEquity 10.908000
earningsGrowth 0.329000
revenueGrowth 0.095000
grossMargins 0.536650
operatingMargins 0.396020
trailingEps 15.300000
forwardEps 21.722450

A current ratio of 2.901 for VRTX implies that the company has ample liquidity to meet its short-term debts. VRTX's cash reserves and current assets should easily cover these obligations, highlighting its financial stability and ability to manage short-term liabilities.
VRTX's Forward PE is positioned well, reflecting a favorable balance between stock price and earnings. The stock isn't overpriced, offering room for growth and making it a potentially rewarding investment as its value has room to rise further.
VRTX's low Debt-to-Equity ratio shows that the company avoids excessive reliance on debt, reducing financial risk. This suggests a more secure financial position with less vulnerability to debt-related risks, making VRTX a stable and conservative investment.
VRTX's positive gross and operating margins indicate the company's ability to operate profitably. These margins reflect strong financial management, with efficient cost control contributing to sustained profitability and a solid financial outlook.
VRTX's forward EPS exceeds its trailing EPS, indicating that the company is projected to be more profitable in the current financial year compared to the previous one. This suggests positive growth and improved earnings, signaling an optimistic outlook for VRTX's financial performance.

Price projections:

Price projections for VRTX
Price projections for VRTX

VRTX's price projections have been revised upward over time, suggesting that analysts are becoming more confident in the company's future. This trend points to increased optimism about VRTX's ability to grow.

Insider Transactions:

Insider Transactions for VRTX
Insider Transactions for VRTX


Recent trading of VRTX stock saw 28 sales, with market price at 468.06678553989957 per share.There were 1 buy transactions of VRTX stock, with market price at 385.6499938964844 per share.The higher number of buys versus sells near VRTX's current price suggests optimism among investors. This buying trend could be interpreted as a sign that the market expects favorable outcomes for the stock in the near future.

Recommendation changes over time:

Recommendations trend for VRTX
Recommendations trend for VRTX


Vertex Pharmaceuticals Incorporated has been receiving a buy bias from analysts, indicating confidence in its investment potential. This could drive more investors to view Vertex Pharmaceuticals Incorporated as a reliable choice for their money, offering a promising avenue for future growth and financial gains.